CN117377683A - New antigenic peptide and application thereof in treating BRAF gene mutation related diseases - Google Patents
New antigenic peptide and application thereof in treating BRAF gene mutation related diseases Download PDFInfo
- Publication number
- CN117377683A CN117377683A CN202280017212.3A CN202280017212A CN117377683A CN 117377683 A CN117377683 A CN 117377683A CN 202280017212 A CN202280017212 A CN 202280017212A CN 117377683 A CN117377683 A CN 117377683A
- Authority
- CN
- China
- Prior art keywords
- cell
- peptide
- vector
- cells
- neoantigenic peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 170
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 20
- 201000010099 disease Diseases 0.000 title description 13
- 230000000890 antigenic effect Effects 0.000 title description 7
- 206010064571 Gene mutation Diseases 0.000 title description 5
- 101150048834 braF gene Proteins 0.000 title description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 104
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 70
- 201000011510 cancer Diseases 0.000 claims abstract description 36
- 230000035772 mutation Effects 0.000 claims abstract description 33
- 230000027455 binding Effects 0.000 claims abstract description 30
- 102200055421 rs121913355 Human genes 0.000 claims abstract description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 44
- 239000013598 vector Substances 0.000 claims description 39
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 28
- 108091033319 polynucleotide Proteins 0.000 claims description 27
- 102000040430 polynucleotide Human genes 0.000 claims description 27
- 239000002157 polynucleotide Substances 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091008874 T cell receptors Proteins 0.000 claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 239000013603 viral vector Substances 0.000 claims description 18
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 17
- 239000013612 plasmid Substances 0.000 claims description 17
- 239000005557 antagonist Substances 0.000 claims description 16
- 229940126546 immune checkpoint molecule Drugs 0.000 claims description 16
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 13
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 13
- 239000002955 immunomodulating agent Substances 0.000 claims description 13
- 229940121354 immunomodulator Drugs 0.000 claims description 13
- 230000002584 immunomodulator Effects 0.000 claims description 13
- 239000003446 ligand Substances 0.000 claims description 13
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 11
- -1 0X40 Proteins 0.000 claims description 10
- 108010002350 Interleukin-2 Proteins 0.000 claims description 10
- 102000000588 Interleukin-2 Human genes 0.000 claims description 10
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 10
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 10
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 9
- 230000003213 activating effect Effects 0.000 claims description 9
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 9
- 210000004881 tumor cell Anatomy 0.000 claims description 9
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 8
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 claims description 8
- 102100038078 CD276 antigen Human genes 0.000 claims description 8
- 101710185679 CD276 antigen Proteins 0.000 claims description 8
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 8
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 8
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 8
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 8
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 8
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 8
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 8
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 8
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 8
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 8
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 8
- 102000002698 KIR Receptors Human genes 0.000 claims description 8
- 108010043610 KIR Receptors Proteins 0.000 claims description 8
- 102000017578 LAG3 Human genes 0.000 claims description 8
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 claims description 8
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 claims description 8
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 8
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 8
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 8
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 8
- 239000000556 agonist Substances 0.000 claims description 8
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 7
- 102100027207 CD27 antigen Human genes 0.000 claims description 6
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 claims description 6
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 6
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 6
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 6
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 claims description 6
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000002105 nanoparticle Substances 0.000 claims description 6
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 4
- 241000710929 Alphavirus Species 0.000 claims description 3
- 206010008761 Choriomeningitis lymphocytic Diseases 0.000 claims description 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 3
- 241000701033 Simian cytomegalovirus Species 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 238000005538 encapsulation Methods 0.000 claims description 3
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 claims description 3
- 108010094020 polyglycine Proteins 0.000 claims description 3
- 229920000232 polyglycine polymer Polymers 0.000 claims description 3
- 108010000222 polyserine Proteins 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 abstract description 7
- 238000010276 construction Methods 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 29
- 235000001014 amino acid Nutrition 0.000 description 25
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 20
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 20
- 229960005486 vaccine Drugs 0.000 description 18
- 108010074027 glycyl-seryl-phenylalanine Proteins 0.000 description 17
- 238000011282 treatment Methods 0.000 description 14
- 230000002163 immunogen Effects 0.000 description 13
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 13
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 11
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 11
- 108010047620 Phytohemagglutinins Proteins 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 230000001885 phytohemagglutinin Effects 0.000 description 10
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000011510 Elispot assay Methods 0.000 description 8
- JSLVAHYTAJJEQH-QWRGUYRKSA-N Gly-Ser-Phe Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JSLVAHYTAJJEQH-QWRGUYRKSA-N 0.000 description 8
- 102000043129 MHC class I family Human genes 0.000 description 8
- 108091054437 MHC class I family Proteins 0.000 description 8
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 8
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 108010015792 glycyllysine Proteins 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- LBRCLQMZAHRTLV-ZKWXMUAHSA-N Ile-Gly-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LBRCLQMZAHRTLV-ZKWXMUAHSA-N 0.000 description 6
- VTCKHZJKWQENKX-KBPBESRZSA-N Tyr-Lys-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O VTCKHZJKWQENKX-KBPBESRZSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000007481 next generation sequencing Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- MWQXFDIQXIXPMS-UNQGMJICSA-N Phe-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=CC=C1)N)O MWQXFDIQXIXPMS-UNQGMJICSA-N 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108010051110 tyrosyl-lysine Proteins 0.000 description 5
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108010029697 CD40 Ligand Proteins 0.000 description 4
- 102100032937 CD40 ligand Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 4
- 108010075646 HLA-B18 Antigen Proteins 0.000 description 4
- 108010014597 HLA-B44 Antigen Proteins 0.000 description 4
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 4
- BPGDJSUFQKWUBK-KJEVXHAQSA-N Thr-Val-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BPGDJSUFQKWUBK-KJEVXHAQSA-N 0.000 description 4
- RLVTVHSDKHBFQP-ULQDDVLXSA-N Val-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CC=C(O)C=C1 RLVTVHSDKHBFQP-ULQDDVLXSA-N 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000139 costimulatory effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ZNAPAUSAUBHENO-IHPCNDPISA-N Lys-Trp-His Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CN=CN3)C(=O)O)NC(=O)[C@H](CCCCN)N ZNAPAUSAUBHENO-IHPCNDPISA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 108010029384 tryptophyl-histidine Proteins 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- UAOSDDXCTBIPCA-QXEWZRGKSA-N Arg-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UAOSDDXCTBIPCA-QXEWZRGKSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- MWLYSLMKFXWZPW-ZPFDUUQYSA-N Gln-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O MWLYSLMKFXWZPW-ZPFDUUQYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DTRUBYPMMVPQPD-YUMQZZPRSA-N Gly-Gln-Arg Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DTRUBYPMMVPQPD-YUMQZZPRSA-N 0.000 description 2
- YKJUITHASJAGHO-HOTGVXAUSA-N Gly-Lys-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)CN YKJUITHASJAGHO-HOTGVXAUSA-N 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- NKKFVJRLCCUJNA-QWRGUYRKSA-N Lys-Gly-Lys Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN NKKFVJRLCCUJNA-QWRGUYRKSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 description 2
- 201000001528 bladder urothelial carcinoma Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OEDPHAKKZGDBEV-GFPBKZJXSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2r)-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]-2-(hexadecanoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CCCCCCCCCCCCCCC)CSCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC OEDPHAKKZGDBEV-GFPBKZJXSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000800133 Homo sapiens Thyroglobulin Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- GOWLTLODGKPXMN-MEKRSRHXSA-N OM-174 Chemical compound O1[C@H](OP(O)(O)=O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](O)[C@H](O)[C@H]1CO[C@H]1[C@H](NC(=O)C[C@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](CO)O1 GOWLTLODGKPXMN-MEKRSRHXSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000012648 POLY-ICLC Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 101100276209 Rhizobium meliloti (strain 1021) cya1 gene Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- BEGDZYNDCNEGJZ-XVKPBYJWSA-N Val-Gly-Gln Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O BEGDZYNDCNEGJZ-XVKPBYJWSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 229940008126 aerosol Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- 101150084863 cya gene Proteins 0.000 description 1
- 101150101102 cyaA gene Proteins 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940056913 eftilagimod alfa Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002308 glutamine derivatives Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 229940044600 maleic anhydride Drugs 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940100027 ontak Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 201000004341 pediatric supratentorial ependymoma Diseases 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 108700002563 poly ICLC Proteins 0.000 description 1
- 229940115270 poly iclc Drugs 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000015033 supratentorial ependymoma Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000007482 whole exome sequencing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present disclosure provides an isolated neoantigen peptide comprising a tumor-specific neoepitope capable of binding to MHC-1 to form an MHC-neoantigen complex, a neoantigen binding peptide, a T cell comprising a TCR or CAR comprising the neoantigen binding peptide, and its use for immunotherapy of cancer, particularly cancer with BRAF G469V mutations.
Description
Technical Field
The present application relates generally to immunotherapeutic peptides, nucleic acids encoding said peptides, peptide binders and their use in immunotherapy, for example of cancer, and in particular to neoantigenic peptides and their use for the treatment of BRAF gene mutation related diseases.
Background
Lung cancer has so far been the leading cause of cancer death in men and women, accounting for almost 25% of all cancer deaths. Lung cancer is generally divided into two major types, known as small cell lung cancer and non-small cell lung cancer. Non-small cell lung cancer (NSCLC) is more common than small cell lung cancer, accounting for 85% of all lung cancers. In recent years, clinical application of immunotherapy typified by immunosuppressant (ICI) anti-PD-1/PD-L1 antibodies has brought long-term survival hope to patients with advanced NSCLC. Recent data show that five-year survival rates of patients with advanced NSCLC treated with PD-1 antibody in the first line have reached 23.2% and that patients with PD-1 antibody in the second line have reached 16% and 2-3 times higher than conventional treatment.
Unfortunately, studies to date have shown that advanced NSCLC carrying genetic mutations rarely benefit from ICI immunotherapy for complex reasons, and that the lack of neoantigens in genetically mutated patients is considered one of the main reasons for the inability to stimulate an effective immune response in the body. How to enhance the capability of gene mutation NSCLC patients to respond to ICI, so that the gene mutation NSCLC patients can still benefit from subsequent immunotherapy after targeted therapy drug resistance, has important significance for improving five-year survival rate of advanced NSCLC patients, and is an important problem to be solved in clinical practice.
The potent anti-tumor immunity of humans is associated with the presence of T cells directed against a new antigen of cancer, a class of HLA-binding peptides generated by tumor-specific mutations, and the data presented suggest that recognition of such new antigens is a major factor in clinical immunotherapy activity. Massively parallel whole exome sequencing has been used to detect all mutations within tumors to predict neoantigens. Neoantigen vaccination can expand the existing population of neoantigen-specific T cells and induce new cancer-specific T cells. Thus, neoantigens have emerged as potential ideal targets for anti-tumor immune responses.
The BRAF gene is a protooncogene found on chromosome 7, has abundant amino acids as shown in NCBI reference sequence np_001365403.1, and becomes an oncogene after mutation. Although BRAF mutations and their relationship to cancer were not discovered until 2002, studies conducted hereafter have identified hundreds of different types of mutations that may be associated with cancer. BRAF mutations are classified according to the newly proposed classification scheme into class 1 (kinase activated, codon 600), class 2 (kinase activated, non-codon 600) and class 3 (kinase impaired) (Lokhandwala, p.m., tseng, LH., rodriguez, e.et al, clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing. Bmc Cancer 19,665 (2019)).
However, mutation does not mean successful identification of a new antigen that is immunogenic, let alone the ability to induce antigen-specific cytotoxic T Cells (CTLs) that recognize and lyse cancer or tumor cells. In fact, only a very low proportion of mutations lead to the production of interesting neoantigenic peptides.
Thus, there remains a need in the art to develop additional cancer therapeutics.
Disclosure of Invention
In one aspect, an isolated neoantigenic peptide is provided, wherein the isolated neoantigenic peptide comprises, consists essentially of, or consists of the amino acid sequence set forth in SEQ ID NO. 19 (QRIGSGSFVT) or a functionally equivalent variant of SEQ ID NO. 19.
In some embodiments, the isolated neoantigenic peptide comprises a tumor-specific neoepitope capable of binding MHC-1 to form an MHC-neoantigen complex.
In some embodiments, the functionally equivalent variant hybridizes to SEQ ID NO:19, or comprises one or two amino acid changes compared to SEQ ID No. 19.
In some embodiments, the amino acid change is a conservative amino acid substitution.
In some embodiments, the isolated neoantigenic peptide is linked to one or more additional neoantigenic peptides, optionally via a linker (e.g., a polyglycine or polyserine linker).
In some embodiments, the isolated neoantigenic peptides are about 10 to 30 amino acids in length, such as about 10 to 20 amino acids in length, such as 10, 11, 12, 13, 14, and 15 amino acids in length.
In some embodiments, the isolated neoantigenic peptide binds MHC-1 with a binding affinity of about 500nM or less, e.g., about 250nM or less, or about 50nM or less.
In one aspect, polynucleotides encoding the novel antigenic peptides described herein are provided.
In one aspect, there is provided a vector comprising a polynucleotide described herein.
In some embodiments, the vector is selected from the group consisting of a plasmid, a cosmid, an RNA formulated in a particle, a self-amplifying RNA (SAM), a SAM formulated in a particle, or a viral vector.
In some embodiments, the viral vector is an alphavirus vector, a Venezuelan Equine Encephalitis (VEE) viral vector, a sindbis viral vector, a semliki forest viral vector, a simian or human cytomegalovirus vector, a lymphocytic choriomeningitis viral vector, a retrovirus vector, a lentivirus vector, an adenovirus vector, or a combination thereof.
In one aspect, there is provided a composition comprising an isolated neoantigenic peptide described herein, optionally in the form of an in vivo delivery system, such as nanoparticle encapsulation, virus-like particles, liposomes, or any combination thereof.
In one aspect, provided are compositions comprising the polynucleotides and/or vectors described herein, optionally in the form of an in vivo delivery system, such as a virus, virus-like particle, plasmid, bacterial plasmid, nanoparticle, or any combination thereof.
In some embodiments, the composition further comprises at least one modulator of a checkpoint molecule or an immunomodulatory agent, or a nucleic acid encoding the modulator or immunomodulatory agent, or a vector comprising a nucleic acid encoding the modulator or immunomodulatory agent.
In some embodiments, the modulator of the checkpoint molecule is selected from: (a) Agonists of members of the tumor necrosis factor receptor superfamily, preferably agonists of CD27, CD40, 0X40, GITR or CD 137; (b) Antagonists of PD-1, PD-L1, CD274, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, TIM-3, VISTA, or antagonists of members of the B7-CD28 superfamily, preferably antagonists of CD28 or ICOS, or antagonists of its ligands; or wherein the immunomodulator is a T cell growth factor, preferably IL-2, IL-12 or IL-15.
In some embodiments, the composition further comprises one or more adjuvants.
In one aspect, there is provided a T Cell Receptor (TCR) capable of binding a neoantigenic peptide described herein or an MHC-I-peptide complex comprising a neoantigenic peptide described herein.
In one aspect, there is provided a chimeric antigen receptor comprising: (i) a T cell activating molecule; (ii) a transmembrane region; and (iii) an antigen recognition moiety capable of binding to a neoantigenic peptide described herein or an MHC-peptide complex comprising a neoantigenic peptide described herein.
In one aspect, there is provided a T cell comprising a T cell receptor or chimeric antigen receptor described herein.
In some embodiments, the T cell is a T cell isolated from a population of T cells from a subject that has been incubated with an antigen presenting cell (e.g., an artificial antigen presenting cell) and a neoantigen peptide described herein for a time sufficient to activate the T cell.
In some embodiments, the T cell is a cd8+ T cell or a cytotoxic T cell.
In one aspect, there is provided a method for activating tumor-specific T cells, the method comprising: (a) isolating a population of T cells from a subject; and (b) incubating the isolated population of T cells with antigen presenting cells (e.g., artificial antigen presenting cells) and the neoantigenic peptides described herein for a time sufficient to activate the T cells.
In one aspect, a modified cd8+ T cell transfected or transduced with a nucleic acid encoding a TCR described herein or a chimeric antigen receptor described herein is provided.
In one aspect, provided are compositions comprising T cells described herein, activated tumor-specific T cells produced by the methods described herein, and/or modified cd8+ T cells described herein.
In one aspect, a method of treating or preventing a BRAF mutation related cancer in a subject is provided, the method comprising administering to the subject a therapeutically effective amount of an isolated neoantigenic peptide described herein, a polynucleotide described herein, a vector described herein, a composition described herein, a T cell described herein, an activated tumor-specific T cell produced by a method described herein, and/or a modified cd8+ T cell described herein.
In one aspect, a method of inhibiting the growth of a tumor cell bearing a BRAF mutation is provided, the method comprising administering to a subject a therapeutically effective amount of an isolated neoantigenic peptide described herein, a polynucleotide described herein, a vector described herein, a composition described herein, a T cell described herein, an activated tumor-specific T cell produced by a method described herein, and/or a modified cd8+ T cell described herein.
In some embodiments, the BRAF mutation is a BRAF G469V mutation.
Drawings
In the accompanying drawings, embodiments of the present disclosure are shown by way of example. It is to be expressly understood that the description and drawings are only for the purpose of illustration and aid in understanding and are not intended as a definition of the limits of the invention.
Fig. 1 shows HLA I ELISpot results for BRAF G469V donors.
Fig. 2 shows candidate peptide predictions for BRAF G469V mutation sites. In the predictive model, a high ranking score indicates high binding affinity.
Fig. 3 shows ELISpot results for 35 BRAF G469V peptides.
Fig. 4 shows ELISpot results for 4 BRAF G469V peptides.
Figure 5 shows ELISpot results for healthy donors.
Figure 6 shows ELISpot results for 16 healthy donors.
FIG. 7 shows ELISPot results for 4 HLA A A0201 healthy donors.
FIG. 8 shows a plasmid map of the MSCV plasmid encoding HLA A A0201 and BRAF-19 peptides.
Detailed Description
For the purposes of promoting an understanding of the principles of the disclosure, reference will now be made to the embodiments illustrated in the drawings and specific language will be used to describe the same. However, it should be understood that it is not intended to limit the scope of the present disclosure.
In the present disclosure, unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by one of ordinary skill in the art. Although any methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, the preferred methods and materials are described herein. Accordingly, the terms defined herein are more fully described by reference to the entire specification.
As used herein, the singular terms one (a), one (an) and the plural reference are included unless the context clearly dictates otherwise. Unless otherwise indicated, nucleic acids are written in a 5 'to 3' direction from left to right; the amino acid sequence is written from left to right in the amino to carboxyl direction. It is to be understood that this invention is not limited to the particular methodology, protocols, and reagents described, as these may vary depending upon the context in which one of ordinary skill in the art uses.
As used herein, the term "consisting essentially of" in the context of amino acid sequences means the recited amino acid sequences and additional 1, 2, 3, 4, or 5 amino acids at the N-or C-terminus thereof.
Unless the context requires otherwise, the terms "comprise," "include," and "comprise," or the like, are intended to imply a non-exclusive inclusion, such that an element or feature listed is not limited to only those elements or features listed or stated but may include other elements or features not listed or stated.
The term "optional" or "optionally" means that the subsequently described event, circumstance or replacement may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
As used herein, the term "about" when referring to a given value, e.g., parameter, quantity, etc., is intended to encompass variations in the given value, e.g., +/-10% or less, +/-5% or less, +/-1% or less, and +/-0.1% or less, from the given value.
As used herein, the terms "patient," "individual," and "subject" are used in the context of any mammalian recipient or composition disclosed herein. Accordingly, the methods and compositions disclosed herein may have medical and/or veterinary applications. In a preferred form, the mammal is a human.
As used herein, the term "sequence identity" is intended to include the number of exact nucleotide or amino acid matches, taking into account the proper alignment using standard algorithms, taking into account the degree to which sequences are identical over a comparison window. Thus, the "percent sequence identity" is calculated by: comparing the two optimally aligned sequences over a comparison window, determining the number of positions at which the same nucleobase (e.g., A, T, C, G) occurs in the two sequences to produce the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window (i.e., window size), and multiplying the result by 100 to yield the percentage of sequence identity. For example, "sequence identity" may be understood to mean the "percentage of matches" calculated by the DNASIS computer program (Windows version 2.5; available from Hitachi software engineering Co., of san Francisco, calif.).
New antigens/peptides
As used herein, the term "neoantigen" or "neoantigenic peptide" refers to a class of tumor antigens derived from tumor-specific changes in proteins. New antigens include, but are not limited to, tumor antigens, which result from, for example, substitution of protein sequences, frame shift mutations, in-frame deletions, insertions, and tumor-specific overexpression of polypeptides. The term "tumor-specific change" refers to a change that is not present in a very cancer cell but is found in a cancer or tumor cell.
Because of the technical difficulties of identifying neoantigens, selecting optimized antigens, and producing neoantigens for use in vaccines or immunogenic compositions, neoantigens are rarely used in cancer vaccines or immunogenic compositions.
MHC binding neoantigens are a dynamic process and do not undergo chemical changes during transport. Since the level of activation of T cells is determined by the concentration of successful MHC-neoantigen complexes, the task of finding active neoantigens is shifted to recognition of stable MHC-peptide complexes. The accuracy of predictive algorithms for identifying stable MHC-peptide complexes is driven by the use of validated, combined and non-combined peptide neural network-based learning methods.
Sequencing methods are used to identify tumor-specific mutations. Any suitable sequencing method may be used, such as Next Generation Sequencing (NGS) techniques. "NGS" may include all new high throughput sequencing techniques that read nucleic acid templates in random parallel along the entire genome by dividing the entire genome into small fragments. Such NGS techniques (massively parallel sequencing techniques) are capable of delivering nucleic acid sequence information of a whole genome, an exome, a transcriptome (all transcribed sequences of a genome), or a methylation group (all methylated sequences of a genome) in a very short time.
Herein, the present inventors predicted a neoantigenic peptide sequence of patients with BRAF G469V mutation by NGS and machine learning methods and confirmed the sequence of the amino acid sequence as set forth in SEQ ID NO:19 is capable of activating cd8+ cells, indicating its anti-tumor function in patients with BRAF G469V mutations.
The BRAF G469V mutation results from a single nucleotide change (c.1406g > T), resulting in a glycine (G) at position 469 being substituted with a valine (V) amino acid. BRAF G469V was present in 0.07% of AACR GENIE cases, including lung adenocarcinoma, colon adenocarcinoma, bladder urothelial carcinoma, primary unknown cancer, and primary unknown cancer.
In one aspect, the invention provides an isolated neoantigenic peptide, wherein the isolated neoantigenic peptide comprises the amino acid sequence set forth in SEQ ID NO. 19 (QRIGSGSFVT), or a functionally equivalent variant of SEQ ID NO. 19 (QRIGSGSFVT).
The term "isolated" refers to a material that is substantially or essentially free of components that normally accompany the material when it is found in its natural state. Thus, the isolated neoantigenic peptides described herein do not contain some or all of the materials normally associated with peptides in an in situ environment. An "isolated" neoantigenic peptide refers to a neoantigenic epitope that does not include the entire sequence of the antigen from which the epitope is derived.
In some embodiments, the isolated neoantigenic peptide comprises a tumor-specific neoepitope capable of binding MHC-1 to form an MHC-neoantigen complex. The term "tumor-specific neoepitope" refers to a neoepitope that is not present in normal non-cancerous cells but is found in cancer or tumor cells.
In some embodiments, the present disclosure contemplates functionally equivalent variants of the isolated neoantigenic peptides identified herein. The term "functionally equivalent variant" as used herein means a variant polypeptide species having one or more amino acid substitutions, insertions or deletions compared to a reference peptide, provided that the variant retains or substantially retains its specific binding function. In some embodiments, the functionally equivalent variant hybridizes to SEQ ID NO:19 has at least 80% (e.g., at least 85%, at least 90%, at least 95%, at least 99% or more) sequence identity, or comprises one or two amino acid changes compared to SEQ ID No. 19.
In some embodiments, the amino acid change is a conservative amino acid substitution. "conservative amino acid substitution" refers to an amino acid substitution in which one amino acid residue is replaced with another amino acid residue having a similar side chain. Amino acid residue families having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). For example, substitution of phenylalanine for tyrosine is a conservative substitution. Another example is the substitution of glutamine for glutamic acid or asparagine for aspartic acid, which can be considered a similar substitution, as glutamine and asparagine are the amide derivatives of glutamic acid and aspartic acid, respectively. Methods for identifying nucleotide and amino acid conservative substitutions that do not eliminate peptide function are known to those skilled in the art.
In some embodiments, an isolated neoantigenic peptide as described herein may be linked, optionally through a linker, to one or more additional neoantigenic peptides, preferably to one or more neoantigenic peptides specific for the same tumor or cancer type. It is beneficial to use a combination of different neoantigenic peptides directed against the same tumor or cancer type to induce antigen specific cytotoxic T cells that recognize and lyse tumor cells.
A variety of linkers known in the art (e.g., polyglycine or polyserine linkers) may be used in the present disclosure. For example, short oligopeptides or polypeptide linkers, preferably between 2 and 10 amino acids in length, may form a linkage between the peptides. Glycine-serine doublets provide particularly suitable linkers.
In some embodiments, the isolated neoantigenic peptides are about 10 to 30 amino acids in length, such as about 10 to 20 amino acids in length, such as 10, 11, 12, 13, 14, and 15 amino acids in length. In some embodiments, the isolated neoantigenic peptide is about 10 to about 15 amino acids in length. In some embodiments, the isolated neoantigenic peptide is about 10 to about 11 amino acids in length.
In some embodiments, the isolated neoantigenic peptide binds to class I Major Histocompatibility Complex (MHC). In some embodiments, the isolated neoantigenic peptide binds to MHC class I (MHC-I) with a binding affinity of about 500nM or less. In some embodiments, the isolated neoantigenic peptide binds to MHC-1 with a binding affinity of about 250nM or less. In some embodiments, the isolated neoantigenic peptide binds to MHC-1 with a binding affinity of about 50nM or less. As used herein, the term "major histocompatibility complex" or "MHC" is a cluster of genes that play a role in controlling cellular interactions responsible for physiological immune responses. In humans, MHC complexes are also known as Human Leukocyte Antigen (HLA) complexes. In some embodiments, the MHC complex is HLA class I. In some embodiments, HLA class I may be selected from HLA a0201, HLA a2402, HLA B07, HLA B18, HLA B35, or HLA B44, e.g., HLA a0201. In some embodiments, the neoantigenic peptides described herein have peptide binding specificity common to HLA molecules encoded by two or more HLA alleles.
In some embodiments, the isolated neoantigenic peptide may further comprise modifications that increase in vivo half-life, cell targeting, antigen uptake, antigen processing, MHC-I affinity, MHC stability, antigen presentation, or a combination thereof. In some embodiments, the modification is conjugation to a carrier protein, nanoparticle attachment, nanoparticle encapsulation, conjugation to a ligand, conjugation to an antibody, albumin fusion, fc fusion, cholesterol fusion, pegylation, acylation, amidation, glycosylation, phosphorylation, biotinylation, or addition of an unnatural amino acid.
In some embodiments, provided herein are polynucleotides encoding the novel antigenic peptides described herein. It will be appreciated by those skilled in the art that, due to redundancy of the genetic code, different nucleic acid sequences may encode the same peptide, and that each nucleic acid falls within the scope of the present invention. The coding nucleic acid may be DNA or RNA, e.g. mRNA, or a combination thereof. In some embodiments, the nucleic acid encoding the peptide is a self-amplifying mRNA. Any suitable polynucleotide encoding a neoantigenic peptide described herein falls within the scope of the invention.
In some embodiments, provided herein are vectors, e.g., expression vectors, useful for the production and administration of the novel antigenic peptides described herein. Expression vectors for different cell types are well known in the art and can be selected without undue experimentation. Typically, the DNA is inserted into an expression vector, e.g., a plasmid, in the correct orientation and in the correct reading frame for expression. If desired, the DNA may be linked to appropriate transcriptional and translational regulatory control nucleotide sequences recognized by the desired host (e.g., bacteria), although such control is typically available in expression vectors. The vector is then introduced into host bacteria for cloning using standard techniques (see, e.g., sambrook et al (1989) Molecular Cloning, A Laboratory Manual, cold Spring Harbor Laboratory, cold Spring Harbor, n.y.).
Expression vectors comprising the polynucleotides described herein and host cells comprising the expression vectors are also contemplated. The neoantigenic peptide may be provided in the form of an RNA or cDNA molecule encoding the desired neoantigenic peptide. One or more of the neoantigenic peptides of the invention may be encoded by a single expression vector.
Provided herein are vector systems comprising an expression vector, wherein the expression vector may be selected from a plasmid, a cosmid, an RNA formulated in a particle, a self-amplifying RNA (SAM), a SAM formulated in a particle, or a viral vector. In some embodiments, the viral vector may be an alphavirus vector, a Venezuelan Equine Encephalitis (VEE) viral vector, a sindbis viral vector, a semliki forest viral vector, a simian or human cytomegalovirus vector, a lymphocytic choriomeningitis viral vector, a retrovirus vector, a lentivirus vector, an adenovirus vector, or a combination thereof.
Suitable host cells for expressing the polypeptide include prokaryotes, yeast, insects, or higher eukaryotic cells under the control of a suitable promoter. Prokaryotes include gram-negative or gram-positive organisms, such as E.coli. Higher eukaryotic cells include established mammalian-derived cell lines. Cell-free translation systems may also be used. Suitable cloning and expression vectors for bacterial, fungal, yeast and mammalian cell hosts are well known in the art.
Novel antigen binding peptides
In one aspect, the disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof), or T Cell Receptors (TCRs), or Chimeric Antigen Receptors (CARs) capable of binding with high affinity to a neoantigenic peptide as described herein or an MHC (HLA) -neoantigenic peptide complex as described herein. In some embodiments, the antibody is a monoclonal antibody specific for a neoantigenic peptide described herein.
In some embodiments, provided herein are T Cell Receptors (TCRs) capable of binding to or comprising the neoantigenic peptides described herein or MHC-peptide complexes of the neoantigenic peptides described herein. In some embodiments, the MHC of the MHC-peptide complex is MHC class I. In some embodiments, the TCR may be a bispecific TCR further comprising a domain comprising an antibody or antibody fragment capable of binding an antigen. In some embodiments, the antigen may be a T cell specific antigen, such as CD3. In some embodiments, the antibody or antibody fragment is an anti-CD 3 scFv.
In some embodiments, provided herein is a chimeric antigen receptor comprising: (i) a T cell activating molecule; (ii) a transmembrane region; and (iii) an antigen recognition moiety capable of binding to a neoantigenic peptide described herein or an MHC-peptide complex comprising a neoantigenic peptide described herein. In some embodiments, the T cell activating molecule is CD3- ζ. In some embodiments, the chimeric antigen receptor further comprises a costimulatory signaling domain. In some embodiments, the costimulatory signaling domain may be selected from the group consisting of CD28, 4-1BB, OX40, ITAM, and ICOS. In some embodiments, the antigen recognition moiety is capable of binding to a neoantigenic peptide in the context of class I MHC. In some embodiments, the antigen recognition moiety is an scFv of a monoclonal antibody specific for a neoantigenic peptide described herein. In some embodiments, the MHC of the MHC peptide is MHC class I.
T cell
In one aspect, the present disclosure provides a T cell comprising a T cell receptor or chimeric antigen receptor described herein. Preferably, the T cells are cd8+ T cells or cytotoxic T cells.
In some embodiments, provided herein are T cells comprising a T Cell Receptor (TCR) capable of binding to a neoantigenic peptide described herein or an MHC-peptide complex comprising a neoantigenic peptide described herein, wherein the T cells are T cells isolated from a T cell population from a subject, the T cell population having been incubated with an antigen presenting cell (e.g., an artificial antigen presenting cell) and a neoantigenic peptide described herein for a sufficient time to activate the T cells. In some embodiments, the T cell is a cd8+ T cell or a cytotoxic T cell. In some embodiments, the T cell population from the subject is a cd8+ T cell population from the subject. In some embodiments, activated cd8+ T cells are isolated from antigen presenting cells. In some embodiments, the antigen presenting cells are artificial antigen presenting cells or dendritic cells or CD40L expanded B cells. In some embodiments, the antigen presenting cells are autologous. In some embodiments, the antigen presenting cells have been treated to strip endogenous MHC-related peptides from their surface. In some embodiments, the treatment to strip endogenous MHC-related peptides comprises treating the cells with a weak acid solution. In some embodiments, the antigen presenting cells have been pulsed with a neoantigenic peptide described herein. In some embodiments, pulsing comprises incubating the antigen presenting cells in the presence of at least about 2 μg/ml of the neoantigenic peptides described herein. In some embodiments, the ratio of isolated T cells to antigen presenting cells is between about 0.1:1 to 300:1, e.g., between about 0.5:1 to 200:1, between about 1:1 to 150:1. In some embodiments, in the presence of IL-2 and IL-7 in the incubation of isolated T cell population. In some embodiments, the MHC of the MHC peptide is MHC class I.
In some embodiments, provided herein is a method for activating tumor-specific T cells, the method comprising: isolating a population of T cells from a subject; and incubating the isolated population of T cells with antigen presenting cells and the neoantigenic peptides described herein for a time sufficient to activate the T cells. In some embodiments, the T cell is a cd8+ T cell or a cytotoxic T cell. In some embodiments, the T cell population from the subject is a cd8+ T cell population from the subject. In some embodiments, activated cd8+ T cells are isolated from antigen presenting cells. In some embodiments, the antigen presenting cells are artificial antigen presenting cells or dendritic cells or CD40L expanded B cells. In some embodiments, the antigen presenting cells are autologous. In some embodiments, the antigen presenting cells have been treated to strip endogenous MHC-related peptides from their surface. In some embodiments, the treatment to strip endogenous MHC-related peptides comprises treating the cells with a weak acid solution. In some embodiments, the antigen presenting cells have been pulsed with a neoantigenic peptide described herein. In some embodiments, pulsing comprises incubating the antigen presenting cells in the presence of at least about 2 μg/ml of the neoantigenic peptides described herein. In some embodiments, the ratio of isolated T cells to antigen presenting cells is between about 0.1:1 to 300:1, e.g., between about 0.5:1 to 200:1, between about 1:1 to 150:1. In some embodiments, in the presence of IL-2 and IL-7 in the incubation of isolated T cell population. In some embodiments, the MHC of the MHC peptide is MHC class I.
In some embodiments, provided herein are modified T cells transfected or transduced with nucleic acids encoding a TCR or chimeric antigen receptor as described herein. The polynucleotides or nucleic acids described herein are capable of transducing T cells, thereby producing modified T cells having a TCR or CAR described herein. In some embodiments, the T cell is a CTL. In some embodiments, the CTL is injected into the patient.
Composition and method for producing the same
In one aspect, the disclosure provides a composition (e.g., a pharmaceutical composition) comprising an isolated neoantigenic peptide, an antibody or antigen binding fragment thereof, a polynucleotide, a T cell comprising a TCR or CAR, an activated tumor-specific T cell, and/or a modified cd8+ T cell, as described herein.
In some embodiments, the invention relates to immunogenic compositions, e.g., vaccine compositions, that are capable of eliciting a neoantigen-specific response (e.g., a cell-mediated immune response or a humoral immune response). In some embodiments, the immunogenic composition comprises a neoantigen therapeutic (e.g., peptide, polynucleotide, TCR or CAR-containing cell, antibody, etc.) described herein that corresponds to a tumor-specific neoantigen (e.g., BRAF-19) identified herein. In some embodiments, the immunogenic compositions described herein are capable of eliciting a specific cytotoxic T cell response or B cell response. In some embodiments, provided herein are compositions comprising autologous subject T cells that contain a T cell receptor or chimeric antigen receptor described herein.
In some embodiments, the compositions described herein further comprise at least one modulator or immunomodulator of a checkpoint molecule, or a nucleic acid encoding the modulator or immunomodulator, or a vector comprising a nucleic acid encoding the modulator or immunomodulator. In some embodiments, the modulator of the checkpoint molecule is selected from: (a) Agonists of members of the tumor necrosis factor receptor superfamily, preferably agonists of CD27, CD40, 0X40, GITR or CD 137; (b) Antagonists of PD-1, PD-L1, CD274, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, TIM-3, VISTA, or antagonists of members of the B7-CD28 superfamily, preferably antagonists of CD28 or ICOS, or antagonists of its ligands. In some embodiments, the modulator of the checkpoint molecule is an inhibitor of a checkpoint molecule selected from the group consisting of PD-1, PD-L1, CD274, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, TIM-3, and VISTA. In some embodiments, the inhibitor of the checkpoint molecule interacts with a ligand of a checkpoint molecule selected from the group consisting of PD-1, PD-L1, CD274, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, TIM-3, and VISTA. In some embodiments, the modulator is a costimulatory ligand, a TNF ligand, an Ig superfamily ligand, CD28, CD80, CD86, ICOS, CD40L, OX, CD27, GITR, CD30, DR3, CD69, or 4-1BB. In some embodiments, the immunomodulator is a T cell growth factor, preferably IL-2, IL-12 or IL-15.
In some embodiments, the immunogenic compositions described herein may further comprise an adjuvant and/or carrier. An adjuvant is a substance that, when mixed into an immunogenic composition, can increase or otherwise alter the immune response to a therapeutic agent. The carrier is a scaffold structure, such as a polypeptide or polysaccharide, to which the neoantigen polypeptide or polynucleotide is capable of binding. Optionally, the adjuvant is conjugated covalently or non-covalently to a polypeptide or polynucleotide described herein.
In some embodiments, the adjuvant is selected from the group consisting of aluminum salts, amplivax, monophosphoryl lipid A, ruiximad, beta-glucan, acrylic or methacrylic acid polymers, copolymers of maleic anhydride, poly (I: C), poly-ICLC, IC30, IC31, AS15, BCG, CP-870, cpG7909, cyaA, dSLIM, GM-CSF, imiquimod, imuFact IMP321, ISS, ISCOMATRIX, juvlmmune, lipoVac, MF59, montanide ISA 206VG, montanide ISA 50V2, montanide ISA 51VG, OK-432, OM-174, OM-197-MP-EC, ONTAK, moloTAK, molozenges, almond, molozenges, mileages, and the like,SRL172, YF-17D, R848, pam3Cys and Pam3CSK4.
In some embodiments, the carrier may, for example, confer stability, increase biological activity, or increase serum half-life. The carrier may be any suitable carrier known to those skilled in the art, such as a protein or antigen presenting cell. Carrier proteins may include, but are not limited to, keyhole limpet hemocyanin, serum proteins such as transferrin, bovine serum albumin, human serum albumin, thyroglobulin, or ovalbumin, immunoglobulins, or hormones such as insulin or palmitic acid.
In some embodiments, the pharmaceutical compositions (e.g., immunogenic compositions) described herein for therapeutic treatment are intended for parenteral, topical, nasal, oral, or topical administration. In some embodiments, the pharmaceutical compositions described herein are administered parenterally, for example, intravenously, subcutaneously, intradermally, or intramuscularly. In some embodiments, described herein are compositions for parenteral administration comprising a solution of a neoantigenic peptide, and an immunogenic composition is dissolved or suspended in an acceptable carrier, such as an aqueous carrier. A variety of aqueous carriers may be used, such as water, buffered water, saline, and the like. These compositions may be sterilized by conventional, well-known sterilization techniques, or may be sterile filtered.
In some embodiments, the concentration of the neoantigenic peptides and polynucleotides described herein in the pharmaceutical formulation can vary widely, i.e., from less than about 0.1% up to 50% by weight or more, depending on the particular mode of administration selected.
The neoantigenic peptides and polynucleotides described herein may also be administered via liposomes that target the peptides to specific cellular tissues, such as lymphoid tissues. Liposomes can be formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and sterols, such as cholesterol.
In some embodiments, the pharmaceutical composition may further comprise pharmaceutically acceptable excipients, carriers, buffers, stabilizers, or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The carrier or other material may be selected according to the route of administration. Acceptable carriers, excipients, or stabilizers are those that are non-toxic to the recipient at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzyl ammonium chloride, hexa-methyl ammonium chloride, benzalkonium chloride, benzethonium chloride, phenolic alcohols, butanols or benzyl alcohols, alkyl p-hydroxybenzoates, such as methyl or propyl p-hydroxybenzoate, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol); proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars, such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions, such as sodium; metal complexes (e.g., zinc-protein complexes); and/or nonionic surfactants, e.g. Or polyethylene glycol (PEG).
In some embodiments, vaccines are provided that comprise a neoantigen therapeutic (e.g., peptide, polynucleotide, TCR or CAR-containing cell, antibody, etc.) described herein that corresponds to a tumor-specific neoantigen (e.g., BRAF-19) identified herein. Vaccines can be delivered by a variety of routes. The route of delivery may include, but is not limited to, oral (including buccal and sublingual), parenteral (including intramuscular, intraarterial, intrathecal, intradermal, intraperitoneal, subcutaneous and intravenous), rectal, vaginal, topical, nasal, transdermal patches, pulmonary or suppository administration or in a form suitable for administration by nebulization, inhalation or insufflation. General information about drug delivery systems can be found in Ansel et al, pharmaceutical Dosage Forms and Drug Delivery Systems (Lippencott Williams & Wilkins, baltimore Md. (1999): vaccines described herein can be administered intramuscularly or by subcutaneous or transdermal administration, e.g., by iontophoresis.
In some embodiments, the vaccine may be a formulation suitable for nasal administration, and may include a powder having a particle size, for example, in the range of about 10 to about 500 microns, which is administered by nasal inhalation. The formulation may be a nasal spray, nasal drops or aerosol administration by nebulizer.
In some embodiments, the vaccine may be a liquid formulation, such as a suspension, syrup, or elixir. The vaccine may also be a formulation for parenteral, subcutaneous, intradermal, intramuscular or intravenous administration (e.g., injection administration), such as a sterile suspension or emulsion.
In some embodiments, the vaccine may include a substance for a single immunization or for multiple immunizations (e.g., a "multi-dose" kit). Preservatives are preferably included in the multi-dose composition. As an alternative (or in addition) to including a preservative in the multi-dose composition, the composition may be contained in a container with a sterile adapter to remove substances. In some embodiments, the vaccine may be administered in a dose volume of about 0.5mL or higher, but may be administered at half the dose (e.g., about 0.25 mL) depending on the condition and age of the subject. In some embodiments, the vaccine may be administered at a higher dose, e.g., about 1 mL.
In some embodiments, the vaccine may be administered as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more dose regimen. In some embodiments, the vaccine is administered as a 1, 2, 3, or 4 dose course regimen. In some embodiments, the vaccine is administered as a 1 dose course regimen. In some embodiments, the vaccine is administered as a 2 dose course regimen. In some embodiments, the administration of the first and second doses may be separated by about 1 day, 2 days, 5 days, 7 days, 14 days, 21 days, 30 days, 2 months, 4 months, 6 months, 9 months, 1 year, 1.5 years, 2 years, 3 years, 4 years, or more. The examples of dosages are not limiting and are merely intended to illustrate particular dosing regimens for administering the vaccines described herein.
Method
In one aspect, the present disclosure provides for the use of the neoantigen therapeutics described herein (e.g., peptides, polynucleotides, TCR or CAR-containing cells, antibodies, etc.) in a variety of applications, including, but not limited to, therapeutic and/or prophylactic methods, such as the treatment of cancer. In some embodiments, the method of treatment comprises immunotherapy. In certain embodiments, the novel antigenic peptides described herein are useful for activating, promoting, increasing and/or enhancing an immune response, increasing the immunogenicity of a tumor, inhibiting tumor growth, reducing tumor volume, increasing tumor cell apoptosis, and/or reducing the tumorigenicity of a tumor. The method may be an in vitro, ex vivo or in vivo method. In some embodiments, the activation, promotion, increase, and/or enhancement of an immune response comprises increasing T cell activity. In some embodiments, the activation, promotion, increase, and/or enhancement of an immune response comprises increasing CTL activity.
In some embodiments, the present disclosure provides methods of treating or preventing cancer in a subject, the methods comprising administering to the subject a therapeutically effective amount of an isolated neoantigenic peptide, polynucleotide, vector, composition, T cell, activated tumor-specific T cell, and/or modified cd8+ T cell described herein. In some embodiments, the present disclosure provides methods of inhibiting tumor cell growth comprising administering to a subject a therapeutically effective amount of an isolated neoantigenic peptide, polynucleotide, vector, composition, T cell, activated tumor-specific T cell, and/or modified cd8+ T cell described herein. In some embodiments, the present disclosure provides isolated neoantigenic peptides, polynucleotides, vectors, compositions, T cells, activated tumor-specific T cells, and/or modified cd8+ T cells as described herein for use in treating or preventing cancer in a subject or for inhibiting the growth of tumor cells. In some embodiments, the disclosure provides the use of an isolated neoantigenic peptide, polynucleotide, vector, composition, T cell, activated tumor-specific T cell, and/or modified cd8+ T cell described herein in the manufacture of a pharmaceutical composition (e.g., an immunogenic composition or vaccine) or medicament for treating or preventing cancer or for inhibiting tumor cell growth in a subject. In some embodiments, the cancer is a BRAF mutation-related cancer. In some embodiments, the tumor cells have a BRAF mutation. In some embodiments, the BRAF mutation is a BRAF G469V mutation.
In some embodiments, the cancer is selected from: adrenal cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, glioblastoma, head and neck cancer, renal chromophobe cancer, renal clear cell carcinoma, renal papillary carcinoma, liver cancer, lung adenocarcinoma, lung squamous carcinoma, ovarian cancer, pancreatic cancer, melanoma, gastric cancer, endometrial cancer, and uterine carcinoma sarcoma. In some embodiments, the cancer is selected from: prostate cancer, bladder cancer, lung squamous cell carcinoma, NSCLC, breast cancer, head and neck cancer, lung adenocarcinoma, GBM, glioma, CML, AML, supratentorial ependymoma, acute promyelocytic leukemia, isolated fibroma, and crizotinib resistant cancer. In some embodiments, the cancer is selected from: NSCLC, melanoma, and bladder cancer. In some embodiments, the cancer is selected from: lung adenocarcinoma, colon adenocarcinoma, bladder urothelial carcinoma, primary unknown cancer, and primary unknown cancer. In some embodiments, the cancer cell comprises a BRAF G469V mutation.
In some embodiments, provided herein are methods of treating cancer or eliciting, enhancing or prolonging an anti-tumor response in a subject in need thereof, comprising administering to the subject a peptide, polynucleotide, vector, composition, antibody or cell described herein. In some embodiments, the subject is a human. In some embodiments, the subject has cancer, preferably has a BRAF G469V mutation.
In some embodiments, the method further comprises administering at least one modulator or immunomodulator of a checkpoint molecule, or a nucleic acid encoding the modulator or immunomodulator, or a vector comprising a nucleic acid encoding the modulator or immunomodulator. In some embodiments, the modulator of the checkpoint molecule is selected from: (a) Agonists of members of the tumor necrosis factor receptor superfamily, preferably agonists of CD27, CD40, 0X40, GITR or CD 137; (b) Antagonists of PD-1, PD-L1, CD274, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, TIM-3, VISTA, or antagonists of members of the B7-CD28 superfamily, preferably antagonists of CD28 or ICOS, or antagonists of its ligands. In some embodiments, the modulator of the checkpoint molecule is an inhibitor of a checkpoint molecule selected from the group consisting of PD-1, PD-L1, CD274, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, TIM-3, and VISTA. In some embodiments, the inhibitor of the checkpoint molecule interacts with a ligand of a checkpoint molecule selected from the group consisting of PD-1, PD-L1, CD274, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, TIM-3, and VISTA. In some embodiments, the modulator is a costimulatory ligand, a TNF ligand, an Ig superfamily ligand, CD28, CD80, CD86, ICOS, CD40L, OX, CD27, GITR, CD30, DR3, CD69, or 4-1BB. In some embodiments, the immunomodulator is a T cell growth factor, preferably IL-2, IL-12 or IL-15.
As used herein, "treatment" refers to a therapeutic intervention that at least partially ameliorates, eliminates, or reduces symptoms or pathological signs after the onset of a disease, disorder, or condition (e.g., cancer). Treatment need not be absolutely beneficial to the subject. The beneficial effect can be determined using any method or criteria known to one of ordinary skill.
As used herein, "preventing" or "prevention" refers to a series of actions that begin before the symptoms or pathological signs of a disease, disorder, or condition appear to prevent and/or alleviate the symptoms or pathological signs. It will be appreciated that such prevention need not be absolutely beneficial to the subject. "prophylactic" treatment is a treatment administered to a subject that does not exhibit symptoms of a disease, disorder or condition, or exhibits only early symptoms, with the aim of reducing the risk of developing symptoms or pathological signs of the disease, disorder or condition.
As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount of a therapeutic agent effective to treat or prevent a disease or disorder in a subject or mammal. A therapeutically effective amount of the medicament has a therapeutic effect, and thus can prevent the development of a disease or disorder; slowing the progression or progression of the disease or condition; to some extent, alleviate one or more symptoms associated with the disease or condition; reducing morbidity and mortality; improving the quality of life; or a combination of these effects.
In some embodiments, the subject receives a single dose of cells during treatment, or receives multiple doses of cells, e.g., 2 to 5, 10, 20, or more doses. In some embodiments, the course of treatment lasts about 1 week to 12 months or longer, e.g., 1, 2, 3, or 4 weeks or 2, 3, 4, 5, or 6 months. In some embodiments, the subject may be treated about every 2-4 weeks. One of ordinary skill in the art will appreciate that the dosage and/or interval of administration may be selected based on a variety of factors, such as the weight and/or blood volume of the subject, the condition being treated, the response of the subject, and the like. The exact amount required may vary from subject to subject, depending on a variety of factors, such as the species, age, weight, sex and general condition of the subject, the severity of the disease or disorder, the immunogenic therapeutic agent used, the mode of administration, concurrent therapy, and the like.
An effective amount for use in humans may be determined based on animal models. For example, dosages for humans may be formulated to achieve concentrations of circulation, liver, local and/or gastrointestinal tract found to be effective in animals. Based on animal data and other types of similar data, one skilled in the art can determine an effective amount of vaccine composition suitable for humans.
Those skilled in the art will appreciate that other variations to the embodiments described herein may be practiced without departing from the scope of the invention. Other modifications are therefore possible.
Although the present disclosure has been described and illustrated in an exemplary form with a certain degree of particularity, it should be noted that the description and illustration has been made by way of example only. Many variations in the details of construction and the combination and arrangement of parts and steps are possible. Accordingly, such modifications are intended to be included within the scope of this invention as defined in the claims.
Examples
Materials and methods:
reagent(s)
Peptides were synthesized by Genscript inc. The peptide sequences used in this experiment are shown in the following table:
name of the name | Peptide sequences |
CMV HLA A0201 | NLVPMVATV |
CMV HLA A2402 | QYDPVAALF |
CMV HLA B0702 | TPRVTGGGAM |
CMV HLA B18 | SDEEEAIVAYTL |
CMV HLA B3501 | IPSINVHHY |
CMV HLA B44 | EFFWDANDIY |
Negative control (HIV HLA 0201) | LTFGWCFKL |
PBMC isolation
PBMCs (peripheral blood mononuclear cells) were isolated from human peripheral blood. Whole blood was diluted 1:1 with phosphate buffer and lymphocyte separation solution (Lymphoprep was used TM STEMCELL Technologies) and lymphocyte separation tubes were centrifuged at 1200Xg for 15 minutes to separate PBMC.
The purpose of this step is to achieve density gradient centrifugation of the cellular components by lymphocyte separation fluid, separating PBMCs from different cells such as erythrocytes and platelets.
ELISpot
Human IFN-gamma pre-coated ELISpot kit was purchased from DAKEWEI inc. ELISpot assay was performed according to the experimental protocol. Briefly, 1X10 5 PBMC cells were seeded into each well at 37℃with 5% CO 2 After 48 hours incubation with the peptide, and photographs were taken using a nikon SMZ18 microscope.
Results:
to identify the HLA subtype of BRAF G469V donor, ELISpot assay was performed. A human IFN- γ ELISpot assay designed to detect human IFN- γ secreting cells at a single cell level can be used to quantify the frequency of human IFN- γ secreting cells. This is often used for quantification of cd8+ T cell responses. Herein, previously discovered CMV peptides of HLA a0201, HLA a2402, HLA B07, HLA B18, HLA B35, and HLA B44 were synthesized as indicators to demonstrate donor HLA subtypes.
Mu.g of CMV peptides of HLA A0201, HLA A2402, HLA B07, HLA B18, HLA B35 and HLA B44 were isolated from donor 1X10 5 PBMCs were incubated for 48 hours. HIV peptide sequence (LTFGWCFKL) was used as a negative control and Phytohemagglutinin (PHA) was used as a positive control. IFN-. Gamma.points were seen in both PHA and HLA A0201 groups. Photographs were taken with a microscope after the wells were dried.
The results of figure 1 show that both HLA a0201 and positive control group were positive in ELISpot assay, indicating that the donor carried HLA a0201 subtype.
Prediction results (peptide sequence)
Candidate peptides for the BRAF G469V mutation site of HLA a0201 (from Westlake university) were predicted using a model named REDpepper. In the predictive model, high rank scores represent high binding affinities to human HLA a0201 subtype. BRAF-19 binds to MHC-I with higher affinity than other peptides, as shown in Table 1 and FIG. 2.
TABLE 1 prediction results
We then tested which peptides could activate the secretion of IFN- γ by cd8+ cells. 1 μg peptide with 1x 10 isolated from donor 5 PBMCs were incubated for 48 hours. 35 peptides (1. Mu.g) were isolated from the donor 1X 10 5 PBMCs were incubated for 48 hours. HIV peptide sequence (LTFGWCFKL) was used as a negative control and Phytohemagglutinin (PHA) was used as a positive control. IFN-gamma points were seen in PHA, HLA A0201, and BRAF-19 groups. Photographs were taken with a microscope after the wells were dried. Of the 38 peptides, BRAF-19 peptide (QRIGSGSFVT) was sufficient to activate cd8+ cells as shown by the ELISpot assay and was significantly more immunogenic than all other BRAF peptides (including BRAF-11, 12, 13, 15, 18, 20, 21, 22, 24, 25, 30 and 31), as shown in figure 3.
To further confirm the effectiveness of the BRAF-19 epitope on BRAF G469V donors, we constructed MSCV plasmids encoding HLA A A0201 and BRAF-19 peptides, as shown in FIG. 8. Expressed HLA A0201 and BRAF-19 proteins are anchored on cell membranes, Can activate CD8+ cells. We then transfected BRAF-19MSCV and negative control MSCV plasmids into HEK 293F cells. 24 hours after transfection, at about 1:1 ratio of CD8+ cells to HEK 293F cells, 1X 10 4 HEK 293F cells and 1X 10 5 Is inoculated into ELISpot wells.
Specifically, 4 peptides (BRAF-28, BRAF-31, BRAF-37, BRAF-19; 1. Mu.g) were isolated from 1X 10 isolated from the donor 5 PBMCs were incubated for 48 hours. 293F cells transfected with BRAF-19MSCV and Neg MSCV plasmids were also transfected with 1X 10 5 PBMC inoculation. HIV peptide sequence (LTFGWCFKL) was used as a negative control and Phytohemagglutinin (PHA) was used as a positive control. Photographs were taken with a microscope after the wells were dried. The results of fig. 4 show that the BRAF-19MSCV group has a significant IFN- γ point compared to the negative MSCV group.
To verify the specificity of the BRAF-19 epitope for the non-BRAF-G469V mutant population, we also performed an ELISPot assay on 16 healthy donors. Mu.g of the CMV peptide of HLA A0201, HLA A2402, HLA B MIX (peptide mixture of HLA B07, B18, B35 and B44) was mixed with 1X 10 5 PBMCs were incubated for 48 hours. 293F cells transfected with BRAF-19MSCV and Neg MSCV plasmids were also transfected with 1X 10 5 PBMC inoculation. HIV peptide sequence (LTFGWCFKL) was used as a negative control and Phytohemagglutinin (PHA) was used as a positive control. Photographs were taken with a microscope after the wells were dried. The difference between the BRAF-19 peptide group and the negative peptide group and the difference between the BRAF-19MSCV group and the negative MSCV group were calculated by Prism 5. The results of fig. 5 and 6 show that the difference between the BRAF-19 peptide group and the negative peptide group was 2.5 on average in 16 healthy donors, while in BRAF G469V donors the difference was 31. In the MSCV plasmid transfected group, the difference between the BRAF-19MSCV group and the negative MSCV group among 16 healthy donors was 3.3 on average, while in the BRAF G469V donor, the difference was 39.
Specifically, the results of fig. 7 show that the difference between the BRAF-19 peptide group and the negative peptide group averages 1.5 in the 4 healthy HLA a 0201 donors, while the difference between the BRAF-19MSCV group and the negative MSCV group averages 1.5 in the MSCV plasmid transfected group. The difference between the BRAF-19 peptide group and the negative peptide group and the difference between the BRAF-19MSCV group and the negative MSCV group were calculated by Prism 5.
Conclusion(s)
Taken together, we successfully predicted 38 BRAF G469V neoantigen sequences and further confirmed their ability to activate cd8+ cells by ELISpot assay. We found that only BRAF-19 neoantigenic peptide was able to activate CD8+ cells and demonstrated its specificity in 16 healthy donors by ELISPot assay, indicating that BRAF-19 has anti-tumor function for patients with BRAF G469V mutation.
While embodiments of the invention have been illustrated and described, it is not intended that these embodiments illustrate and describe all possible forms of the invention. Rather, the words used in the specification are words of description rather than limitation, and it is understood that various changes may be made without departing from the spirit and scope of the invention.
The nucleotide sequences of the MSCV plasmids encoding HLA A0201 and BRAF-19 peptides are shown in SEQ ID NO:39, as shown in:
/>
/>
/>
/>
sequence listing
<110> Western lake biomedical technology (Hangzhou) Co., ltd
<120> New antigenic peptides and their use in the treatment of diseases related to mutation of BRAF gene
<130> PF 211213PCT
<150> PCT/CN2021/077930
<151> 2021-02-25
<160> 39
<170> PatentIn version 3.3
<210> 1
<211> 8
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 1
Arg Ile Gly Ser Gly Ser Phe Val
1 5
<210> 2
<211> 8
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 2
Ile Gly Ser Gly Ser Phe Val Thr
1 5
<210> 3
<211> 8
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 3
Gly Ser Gly Ser Phe Val Thr Val
1 5
<210> 4
<211> 8
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 4
Ser Gly Ser Phe Val Thr Val Tyr
1 5
<210> 5
<211> 8
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 5
Gly Ser Phe Val Thr Val Tyr Lys
1 5
<210> 6
<211> 8
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 6
Ser Phe Val Thr Val Tyr Lys Gly
1 5
<210> 7
<211> 8
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 7
Phe Val Thr Val Tyr Lys Gly Lys
1 5
<210> 8
<211> 8
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 8
Val Thr Val Tyr Lys Gly Lys Trp
1 5
<210> 9
<211> 9
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 9
Gln Arg Ile Gly Ser Gly Ser Phe Val
1 5
<210> 10
<211> 9
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 10
Arg Ile Gly Ser Gly Ser Phe Val Thr
1 5
<210> 11
<211> 9
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 11
Ile Gly Ser Gly Ser Phe Val Thr Val
1 5
<210> 12
<211> 9
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 12
Gly Ser Gly Ser Phe Val Thr Val Tyr
1 5
<210> 13
<211> 9
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 13
Ser Gly Ser Phe Val Thr Val Tyr Lys
1 5
<210> 14
<211> 9
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 14
Gly Ser Phe Val Thr Val Tyr Lys Gly
1 5
<210> 15
<211> 9
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 15
Ser Phe Val Thr Val Tyr Lys Gly Lys
1 5
<210> 16
<211> 9
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 16
Phe Val Thr Val Tyr Lys Gly Lys Trp
1 5
<210> 17
<211> 9
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 17
Val Thr Val Tyr Lys Gly Lys Trp His
1 5
<210> 18
<211> 10
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 18
Gly Gln Arg Ile Gly Ser Gly Ser Phe Val
1 5 10
<210> 19
<211> 10
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 19
Gln Arg Ile Gly Ser Gly Ser Phe Val Thr
1 5 10
<210> 20
<211> 10
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 20
Arg Ile Gly Ser Gly Ser Phe Val Thr Val
1 5 10
<210> 21
<211> 10
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 21
Ile Gly Ser Gly Ser Phe Val Thr Val Tyr
1 5 10
<210> 22
<211> 10
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 22
Gly Ser Gly Ser Phe Val Thr Val Tyr Lys
1 5 10
<210> 23
<211> 10
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 23
Ser Gly Ser Phe Val Thr Val Tyr Lys Gly
1 5 10
<210> 24
<211> 10
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 24
Gly Ser Phe Val Thr Val Tyr Lys Gly Lys
1 5 10
<210> 25
<211> 10
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 25
Ser Phe Val Thr Val Tyr Lys Gly Lys Trp
1 5 10
<210> 26
<211> 10
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 26
Phe Val Thr Val Tyr Lys Gly Lys Trp His
1 5 10
<210> 27
<211> 10
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 27
Val Thr Val Tyr Lys Gly Lys Trp His Gly
1 5 10
<210> 28
<211> 11
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 28
Val Gly Gln Arg Ile Gly Ser Gly Ser Phe Val
1 5 10
<210> 29
<211> 11
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 29
Gly Gln Arg Ile Gly Ser Gly Ser Phe Val Thr
1 5 10
<210> 30
<211> 11
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 30
Gln Arg Ile Gly Ser Gly Ser Phe Val Thr Val
1 5 10
<210> 31
<211> 11
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 31
Arg Ile Gly Ser Gly Ser Phe Val Thr Val Tyr
1 5 10
<210> 32
<211> 11
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 32
Ile Gly Ser Gly Ser Phe Val Thr Val Tyr Lys
1 5 10
<210> 33
<211> 11
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 33
Gly Ser Gly Ser Phe Val Thr Val Tyr Lys Gly
1 5 10
<210> 34
<211> 11
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 34
Ser Gly Ser Phe Val Thr Val Tyr Lys Gly Lys
1 5 10
<210> 35
<211> 11
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 35
Gly Ser Phe Val Thr Val Tyr Lys Gly Lys Trp
1 5 10
<210> 36
<211> 11
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 36
Ser Phe Val Thr Val Tyr Lys Gly Lys Trp His
1 5 10
<210> 37
<211> 11
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 37
Phe Val Thr Val Tyr Lys Gly Lys Trp His Gly
1 5 10
<210> 38
<211> 11
<212> PRT
<213> artificial sequence
<220>
<223> construction
<400> 38
Val Thr Val Tyr Lys Gly Lys Trp His Gly Asp
1 5 10
<210> 39
<211> 8841
<212> DNA
<213> artificial sequence
<220>
<223> construction
<400> 39
acgcgtgtag tcttatgcaa tactcttgta gtcttgcaac atggtaacga tgagttagca 60
acatgcctta caaggagaga aaaagcaccg tgcatgccga ttggtggaag taaggtggta 120
cgatcgtgcc ttattaggaa ggcaacagac gggtctgaca tggattggac gaaccactga 180
attgccgcat tgcagagata ttgtatttaa gtgcctagct cgatacaata aacgggtctc 240
tctggttaga ccagatctga gcctgggagc tctctggcta actagggaac ccactgctta 300
agcctcaata aagcttgcct tgagtgcttc aagtagtgtg tgcccgtctg ttgtgtgact 360
ctggtaacta gagatccctc agaccctttt agtcagtgtg gaaaatctct agcagtggcg 420
cccgaacagg gacctgaaag cgaaagggaa accagagctc tctcgacgca ggactcggct 480
tgctgaagcg cgcacggcaa gaggcgaggg gcggcgactg gtgagtacgc caaaaatttt 540
gactagcgga ggctagaagg agagagatgg gtgcgagagc gtcagtatta agcgggggag 600
aattagatcg cgatgggaaa aaattcggtt aaggccaggg ggaaagaaaa aatataaatt 660
aaaacatata gtatgggcaa gcagggagct agaacgattc gcagttaatc ctggcctgtt 720
agaaacatca gaaggctgta gacaaatact gggacagcta caaccatccc ttcagacagg 780
atcagaagaa cttagatcat tatataatac agtagcaacc ctctattgtg tgcatcaaag 840
gatagagata aaagacacca aggaagcttt agacaagata gaggaagagc aaaacaaaag 900
taagaccacc gcacagcaag cggccactga tcttcagacc tggaggagga gatatgaggg 960
acaattggag aagtgaatta tataaatata aagtagtaaa aattgaacca ttaggagtag 1020
cacccaccaa ggcaaagaga agagtggtgc agagagaaaa aagagcagtg ggaataggag 1080
ctttgttcct tgggttcttg ggagcagcag gaagcactat gggcgcagcc tcaatgacgc 1140
tgacggtaca ggccagacaa ttattgtctg gtatagtgca gcagcagaac aatttgctga 1200
gggctattga ggcgcaacag catctgttgc aactcacagt ctggggcatc aagcagctcc 1260
aggcaagaat cctggctgtg gaaagatacc taaaggatca acagctcctg gggatttggg 1320
gttgctctgg aaaactcatt tgcaccactg ctgtgccttg gaatgctagt tggagtaata 1380
aatctctgga acagattgga atcacacgac ctggatggag tgggacagag aaattaacaa 1440
ttacacaagc ttaatacact ccttaattga agaatcgcaa aaccagcaag aaaagaatga 1500
acaagaatta ttggaattag ataaatgggc aagtttgtgg aattggttta acataacaaa 1560
ttggctgtgg tatataaaat tattcataat gatagtagga ggcttggtag gtttaagaat 1620
agtttttgct gtactttcta tagtgaatag agttaggcag ggatattcac cattatcgtt 1680
tcagacccac ctcccaaccc cgaggggacc cgacaggccc gaaggaatag aagaagaagg 1740
tggagagaga gacagagaca gatccattcg attagtgaac ggatctcgac ggttaacttt 1800
taaaagaaaa ggggggattg gggggtacag tgcaggggaa agaatagtag acataatagc 1860
aacagacata caaactaaag aattacaaaa acaaattaca aaaattcaaa attttatcga 1920
tactagagct agagctagca tgtctcgctc cgtggcctta gctgtgctcg cgctactctc 1980
tctttctggc ctggaggctc agaggatcgg cagcggcagc ttcgtgaccg gctgcggcgc 2040
ctccggtggc ggtggctccg gcggtggtgg gtccatccag cgtactccaa agattcaggt 2100
ttactcacgt catccagcag agaatggaaa gtcaaatttc ctgaattgct atgtgtctgg 2160
gtttcatcca tccgacattg aagttgactt actgaagaat ggagagagaa ttgaaaaagt 2220
ggagcattca gacttgtctt tcagcaagga ctggtctttc tatctcttgt actacactga 2280
attcaccccc actgaaaaag atgagtatgc ctgccgtgtg aaccatgtga ctttgtcaca 2340
gcccaagata gttaagtggg atcgagacat gggtggcggt ggctccggcg gtggtgggtc 2400
cggtggcggt ggctccggcg gtggtgggtc cggcagccac agcatgaggt acttcttcac 2460
cagcgtgagc aggcccggca ggggcgagcc caggttcatc gccgtgggct acgtggacga 2520
cacccagttc gtgaggttcg acagcgacgc cgccagccag aggatggagc ccagggcccc 2580
ctggatcgag caggagggcc ccgagtactg ggacggcgag accaggaagg tgaaggccca 2640
cagccagacc cacagggtgg acctgggcac cctgaggggc tactacaacc agagcgaggc 2700
cggcagccac accgtgcaga ggatgtacgg ctgcgacgtg ggcagcgact ggaggttcct 2760
gaggggctac caccagtacg cctacgacgg caaggactac atcgccctga aggaggacct 2820
gaggagctgg accgccgccg acatggccgc ccagaccacc aagcacaagt gggaggccgc 2880
ccacgtggcc gagcagctga gggcctacct ggagggcacc tgcgtggagt ggctgaggag 2940
gtacctggag aacggcaagg agaccctgca gaggaccgac gcccccaaga cccacatgac 3000
ccaccacgcc gtgagcgacc acgaggccac cctgaggtgc tgggccctga gcttctaccc 3060
cgccgagatc accctgacct ggcagaggga cggcgaggac cagaccaccg agctggtgga 3120
gaccaggccc gccggcgacg gcaccttcca gaagtgggcc gccgtggtgg tgcccagcgg 3180
ccaggagcag aggtacacct gccacgtgca gcacgagggc ctgcccaagc ccctgaccct 3240
gaggtgggag atggccgccg ccctggaggt gtccttaagt accactgagg tggcaatgca 3300
cacttcaact tcttcttcag tcacaaagag ttacatctca tcacagacaa atgatacgca 3360
caaacgggac acatatgcag ccactcctag agctcatgaa gtttcagaaa tttctgttag 3420
aactgtttac cctccagaag aggaaaccgg agaaagggta caacttgccc atcatttctc 3480
tgaaccagag ataacactca ttatttttgg ggtgatggct ggtgttattg gaacgatcct 3540
cttaatttct tacggtattc gccgactgat aaagaaaagc ccatctgatg taaaacctct 3600
cccctcacct gacacagacg tgcctttaag ttctgttgaa atagaaaatc cagagacaag 3660
tgatcaagcg gccgctgagg gcagaggaag tcttctaaca tgcggtgacg tggaggagaa 3720
tcccggccct tccggaatgg agagcgacga gagcggcctg cccgccatgg agatcgagtg 3780
ccgcatcacc ggcaccctga acggcgtgga gttcgagctg gtgggcggcg gagagggcac 3840
ccccaagcag ggccgcatga ccaacaagat gaagagcacc aaaggcgccc tgaccttcag 3900
cccctacctg ctgagccacg tgatgggcta cggcttctac cacttcggca cctaccccag 3960
cggctacgag aaccccttcc tgcacgccat caacaacggc ggctacacca acacccgcat 4020
cgagaagtac gaggacggcg gcgtgctgca cgtgagcttc agctaccgct acgaggccgg 4080
ccgcgtgatc ggcgacttca aggtggtggg caccggcttc cccgaggaca gcgtgatctt 4140
caccgacaag atcatccgca gcaacgccac cgtggagcac ctgcacccca tgggcgataa 4200
cgtgctggtg ggcagcttcg cccgcacctt cagcctgcgc gacggcggct actacagctt 4260
cgtggtggac agccacatgc acttcaagag cgccatccac cccagcatcc tgcagaacgg 4320
gggccccatg ttcgccttcc gccgcgtgga ggagctgcac agcaacaccg agctgggcat 4380
cgtggagtac cagcacgcct tcaagacccc catcgccttc gccagatccc gcgctcagtc 4440
gtccaattct gccgtggacg gcaccgccgg acccggctcc accggatctc gctagagctg 4500
aatctaagtc gacaatcaac ctctggatta caaaatttgt gaaagattga ctggtattct 4560
taactatgtt gctcctttta cgctatgtgg atacgctgct ttaatgcctt tgtatcatgc 4620
tattgcttcc cgtatggctt tcattttctc ctccttgtat aaatcctggt tgctgtctct 4680
ttatgaggag ttgtggcccg ttgtcaggca acgtggcgtg gtgtgcactg tgtttgctga 4740
cgcaaccccc actggttggg gcattgccac cacctgtcag ctcctttccg ggactttcgc 4800
tttccccctc cctattgcca cggcggaact catcgccgcc tgccttgccc gctgctggac 4860
aggggctcgg ctgttgggca ctgacaattc cgtggtgttg tcggggaaat catcgtcctt 4920
tccttggctg ctcgcctgtg ttgccacctg gattctgcgc gggacgtcct tctgctacgt 4980
cccttcggcc ctcaatccag cggaccttcc ttcccgcggc ctgctgccgg ctctgcggcc 5040
tcttccgcgt cttcgccttc gccctcagac gagtcggatc tccctttggg ccgcctcccc 5100
gcctggtacc tttaagacca atgacttaca aggcagctgt agatcttagc cactttttaa 5160
aagaaaaggg gggactggaa gggctaattc actcccaacg atgtcaagaa ttgtgaaaga 5220
ccccacctgt aggtttggca agttagctta agtaacgcca ttttgcaagg catggaaaat 5280
acataactga gaatagagaa gttcagatca aggttaggaa cagagagaca gcagaatatg 5340
ggccaaacag gatatctgtg gtaagcagtt cctgccccgg ctcagggcca agaacagatg 5400
gtccccagat gcggtcccgc cctcagcagt ttctagcgaa ccatcagatg tttccagggt 5460
gccccaagga cctgaaatga ccctgtgcct tatttgaact aaccaatcag tttgcttctt 5520
gcttctgttt gtgtgcttct gctccctgag ctcaataaaa gagcccacaa cccctcactt 5580
ggtgggccag tcctctgata gactgtgtcc cctggatacc cgtatatcga ttctgctttt 5640
tgcttctact gggtctctct ggttagacca gatctgagcc tgggagctct ctggctaact 5700
agggaaccca ctgcttaagc ctcaataaag cttgccttga gtgcttcaag tagtgtgtgc 5760
ccgtctgttg tgtgactctg gtaactagag atccctcaga cccttttagt cagtgtggaa 5820
aatctctagc agtagtagtt catgtcatct tattattcag tatttataac ttgcaaagaa 5880
atgaatatca gagagtgaga ggaacttgtt tattgcagct tataatggtt acaaataaag 5940
caatagcatc acaaatttca caaataaagc atttttttca ctgcattcta gttgtggttt 6000
gtccaaactc atcaatgtat cttatcatgt ctggctctag ctatcccgcc cctaactccg 6060
cccagttccg cccattctcc gccccatggc tgactaattt tttttattta tgcagaggcc 6120
gaggccgcct cggcctctga gctattccag aagtagtgag gaggcttttt tggaggccta 6180
gacttttgca gagacggccc aaattcgtaa tcatggtcat agctgtttcc tgtgtgaaat 6240
tgttatccgc tcacaattcc acacaacata cgagccggaa gcataaagtg taaagcctgg 6300
ggtgcctaat gagtgagcta actcacatta attgcgttgc gctcactgcc cgctttccag 6360
tcgggaaacc tgtcgtgcca gctgcattaa tgaatcggcc aacgcgcggg gagaggcggt 6420
ttgcgtattg ggcgctcttc cgcttcctcg ctcactgact cgctgcgctc ggtcgttcgg 6480
ctgcggcgag cggtatcagc tcactcaaag gcggtaatac ggttatccac agaatcaggg 6540
gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa ccgtaaaaag 6600
gccgcgttgc tggcgttttt ccataggctc cgcccccctg acgagcatca caaaaatcga 6660
cgctcaagtc agaggtggcg aaacccgaca ggactataaa gataccaggc gtttccccct 6720
ggaagctccc tcgtgcgctc tcctgttccg accctgccgc ttaccggata cctgtccgcc 6780
tttctccctt cgggaagcgt ggcgctttct catagctcac gctgtaggta tctcagttcg 6840
gtgtaggtcg ttcgctccaa gctgggctgt gtgcacgaac cccccgttca gcccgaccgc 6900
tgcgccttat ccggtaacta tcgtcttgag tccaacccgg taagacacga cttatcgcca 6960
ctggcagcag ccactggtaa caggattagc agagcgaggt atgtaggcgg tgctacagag 7020
ttcttgaagt ggtggcctaa ctacggctac actagaagga cagtatttgg tatctgcgct 7080
ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg caaacaaacc 7140
accgctggta gcggtggttt ttttgtttgc aagcagcaga ttacgcgcag aaaaaaagga 7200
tctcaagaag atcctttgat cttttctacg gggtctgacg ctcagtggaa cgaaaactca 7260
cgttaaggga ttttggtcat gagattatca aaaaggatct tcacctagat ccttttaaat 7320
taaaaatgaa gttttaaatc aatctaaagt atatatgagt aaacttggtc tgacagttac 7380
caatgcttaa tcagtgaggc acctatctca gcgatctgtc tatttcgttc atccatagtt 7440
gcctgactcc ccgtcgtgta gataactacg atacgggagg gcttaccatc tggccccagt 7500
gctgcaatga taccgcgaga cccacgctca ccggctccag atttatcagc aataaaccag 7560
ccagccggaa gggccgagcg cagaagtggt cctgcaactt tatccgcctc catccagtct 7620
attaattgtt gccgggaagc tagagtaagt agttcgccag ttaatagttt gcgcaacgtt 7680
gttgccattg ctacaggcat cgtggtgtca cgctcgtcgt ttggtatggc ttcattcagc 7740
tccggttccc aacgatcaag gcgagttaca tgatccccca tgttgtgcaa aaaagcggtt 7800
agctccttcg gtcctccgat cgttgtcaga agtaagttgg ccgcagtgtt atcactcatg 7860
gttatggcag cactgcataa ttctcttact gtcatgccat ccgtaagatg cttttctgtg 7920
actggtgagt actcaaccaa gtcattctga gaatagtgta tgcggcgacc gagttgctct 7980
tgcccggcgt caatacggga taataccgcg ccacatagca gaactttaaa agtgctcatc 8040
attggaaaac gttcttcggg gcgaaaactc tcaaggatct taccgctgtt gagatccagt 8100
tcgatgtaac ccactcgtgc acccaactga tcttcagcat cttttacttt caccagcgtt 8160
tctgggtgag caaaaacagg aaggcaaaat gccgcaaaaa agggaataag ggcgacacgg 8220
aaatgttgaa tactcatact cttccttttt caatattatt gaagcattta tcagggttat 8280
tgtctcatga gcggatacat atttgaatgt atttagaaaa ataaacaaat aggggttccg 8340
cgcacatttc cccgaaaagt gccacctgac gtctaagaaa ccattattat catgacatta 8400
acctataaaa ataggcgtat cacgaggccc tttcgtctcg cgcgtttcgg tgatgacggt 8460
gaaaacctct gacacatgca gctcccggag acggtcacag cttgtctgta agcggatgcc 8520
gggagcagac aagcccgtca gggcgcgtca gcgggtgttg gcgggtgtcg gggctggctt 8580
aactatgcgg catcagagca gattgtactg agagtgcacc atatgcggtg tgaaataccg 8640
cacagatgcg taaggagaaa ataccgcatc aggcgccatt cgccattcag gctgcgcaac 8700
tgttgggaag ggcgatcggt gcgggcctct tcgctattac gccagctggc gaaaggggga 8760
tgtgctgcaa ggcgattaag ttgggtaacg ccagggtttt cccagtcacg acgttgtaaa 8820
acgacggcca gtgccaagct g 8841
Claims (27)
1. An isolated neoantigenic peptide, wherein the isolated neoantigenic peptide comprises the amino acid sequence set forth in SEQ ID No. 19 (QRIGSGSFVT), or a functionally equivalent variant of SEQ ID No. 19.
2. The isolated neoantigenic peptide of claim 1, wherein the isolated neoantigenic peptide comprises a tumor-specific neoepitope capable of binding MHC-1 to form an MHC-neoantigenic complex.
3. The isolated neoantigenic peptide of claim 1 or 2, wherein the functionally equivalent variant has at least 80% sequence identity to SEQ ID No. 19 or comprises one or two amino acid changes compared to SEQ ID No. 19.
4. The isolated neoantigenic peptide of claim 3, wherein the amino acid change is a conservative amino acid substitution.
5. The isolated neoantigenic peptide of any one of claims 1-4, wherein the isolated neoantigenic peptide is linked to one or more additional neoantigenic peptides, optionally via a linker, such as a polyglycine or polyserine linker.
6. The isolated neoantigenic peptide of any one of claims 1-5, wherein the isolated neoantigenic peptide is about 10 to 30 amino acids in length, such as about 10 to 20 amino acids in length, such as 10, 11, 12, 13, 14 and 15 amino acids in length.
7. The isolated neoantigenic peptide of any one of claims 1-6, wherein the isolated neoantigenic peptide binds MHC-1 with a binding affinity of about 500nM or less, such as about 250nM or less, or about 50nM or less.
8. A polynucleotide encoding the neoantigenic peptide of any one of claims 1 to 7.
9. A vector comprising the polynucleotide of claim 8.
10. The vector of claim 9, wherein the vector is selected from the group consisting of a plasmid, a cosmid, an RNA formulated in a particle, a self-amplifying RNA (SAM), a SAM formulated in a particle, or a viral vector.
11. The vector of claim 10, wherein the viral vector is an alphavirus vector, a Venezuelan Equine Encephalitis (VEE) viral vector, a sindbis viral vector, a semliki forest viral vector, a simian or human cytomegalovirus vector, a lymphocytic choriomeningitis viral vector, a retrovirus vector, a lentivirus vector, an adenovirus vector, or a combination thereof.
12. A composition comprising the isolated neoantigenic peptide of any one of claims 1 to 7, optionally in the form of an in vivo delivery system, such as nanoparticle encapsulation, virus-like particles, liposomes, or any combination thereof.
13. A composition comprising the polynucleotide of claim 8 and/or the vector of any one of claims 9-11, optionally in the form of an in vivo delivery system, such as a virus, virus-like particle, plasmid, bacterial plasmid, nanoparticle, or any combination thereof.
14. The composition of claim 12 or 13, wherein the composition further comprises at least one modulator or immunomodulator of a checkpoint molecule, or a nucleic acid encoding the modulator or immunomodulator, or a vector comprising a nucleic acid encoding the modulator or immunomodulator.
15. The composition of claim 14, wherein the modulator of the checkpoint molecule is selected from the group consisting of: (a) Agonists of members of the tumor necrosis factor receptor superfamily, preferably agonists of CD27, CD40, 0X40, GITR or CD 137; (b) Antagonists of PD-1, PD-L1, CD274, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, TIM-3, VISTA, or antagonists of members of the B7-CD28 superfamily, preferably antagonists of CD28 or ICOS, or antagonists of its ligands; or wherein the immunomodulator is a T cell growth factor, preferably IL-2, IL-12 or IL-15.
16. The composition of any one of claims 12 to 15, further comprising one or more adjuvants.
17. A T Cell Receptor (TCR) capable of binding the neoantigenic peptide of any one of claims 1-7 or an MHC-I-peptide complex comprising the neoantigenic peptide of any one of claims 1-7.
18. A chimeric antigen receptor comprising: (i) a T cell activating molecule; (ii) a transmembrane region; and (iii) an antigen recognition moiety capable of binding to the neoantigenic peptide of any one of claims 1 to 7 or to an MHC-peptide complex comprising the neoantigenic peptide of any one of claims 1 to 7.
19. A T cell comprising the T cell receptor of claim 17 or the chimeric antigen receptor of claim 18.
20. The T cell of claim 19, wherein the T cell is a T cell isolated from a population of T cells from a subject, the population of T cells having been incubated with an antigen presenting cell, such as an artificial antigen presenting cell, and the neoantigen peptide of any one of claims 1-7 for a time sufficient to activate the T cell.
21. The T cell of claim 19 or 20, wherein the T cell is a cd8+ T cell or a cytotoxic T cell.
22. A method of activating tumor-specific T cells, the method comprising: (a) isolating a population of T cells from a subject; and (b) incubating the isolated population of T cells with antigen presenting cells, such as artificial antigen presenting cells, and the neoantigenic peptide of any one of claims 1-7 for a time sufficient to activate the T cells.
23. A modified cd8+ T cell transfected or transduced with a nucleic acid encoding the TCR of claim 17 or the chimeric antigen receptor of claim 18.
24. A composition comprising the T cell of any one of claims 19-21, an activated tumor-specific T cell produced by the method of claim 22, and/or the modified cd8+ T cell of claim 23.
25. A method of treating or preventing BRAF mutation related cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of the isolated neoantigenic peptide of any one of claims 1 to 7, the polynucleotide of claim 8, the vector of any one of claims 9-11, the composition of any one of claims 12-16 and 24, the T cell of any one of claims 19-21, an activated tumor-specific T cell produced by the method of claim 22, and/or the modified cd8+ T cell of claim 23.
26. A method of inhibiting the growth of a tumor cell bearing a BRAF mutation, the method comprising administering to the subject a therapeutically effective amount of the isolated neoantigenic peptide of any one of claims 1-7, the polynucleotide of claim 8, the vector of any one of claims 9-11, the composition of any one of claims 12-16 and 24, the T cell of any one of claims 19-21, an activated tumor-specific T cell produced by the method of claim 22, and/or the modified cd8+ T cell of claim 23.
27. The method of claim 25 or 26, wherein the BRAF mutation is a BRAF G469V mutation.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021077930 | 2021-02-25 | ||
CNPCT/CN2021/077930 | 2021-02-25 | ||
PCT/CN2022/077710 WO2022179568A1 (en) | 2021-02-25 | 2022-02-24 | Neoantigenic peptide and its use for treating braf gene mutation related diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117377683A true CN117377683A (en) | 2024-01-09 |
Family
ID=83047907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280017212.3A Pending CN117377683A (en) | 2021-02-25 | 2022-02-24 | New antigenic peptide and application thereof in treating BRAF gene mutation related diseases |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117377683A (en) |
WO (1) | WO2022179568A1 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20200476A (en) * | 2015-05-20 | 2020-12-02 | Dana Farber Cancer Inst Inc | Shared neoantigens |
US20190307868A1 (en) * | 2016-03-31 | 2019-10-10 | Neon Therapeutics, Inc. | Neoantigens and methods of their use |
SG10202105561PA (en) * | 2016-11-30 | 2021-07-29 | Advaxis Inc | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
AU2018269982B2 (en) * | 2017-05-16 | 2024-06-13 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating cancer with atypical BRAF mutations |
TW202043256A (en) * | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | Prostate neoantigens and their uses |
-
2022
- 2022-02-24 CN CN202280017212.3A patent/CN117377683A/en active Pending
- 2022-02-24 WO PCT/CN2022/077710 patent/WO2022179568A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2022179568A1 (en) | 2022-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019283892B2 (en) | Anti-human papillomavirus 16 E7 T cell receptors | |
CN107573419A (en) | A kind of nucleic acid molecules for strengthening T cell antitumor activity | |
US20040208850A1 (en) | Modified vaccinia ankara expressing p53 in cancer immunotherapy | |
KR101941893B1 (en) | Genetic marker for discriminating level of meat quality of pig and use thereof | |
TW202332690A (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
CN110592108B (en) | Infectious recombinant cloning method for II-type VII-type epidemic NDV strain DHN3 | |
CN108913718A (en) | A kind of preparation method and application of the CAR-T cell of targeting EGFR v III | |
CN112481271B (en) | Transcription factor C/EBPZ for regulating and controlling formation of adipocytes and application thereof | |
CN107338224A (en) | PD 1 knocks out the preparation of EGFRvIIICAR T cells | |
CN108103088B (en) | Optimized gene of recombinant GLP-1 analogue Fc fusion protein and application thereof | |
CN106591371A (en) | CD16A/GPC3 double-antibody lentivirus expression vector, and construction method and application thereof | |
CN107936122A (en) | A kind of slow virus and its preparation method and application | |
CN113943737A (en) | Application of chicken CTGF gene in inhibiting differentiation of chicken preadipocytes | |
CN109652381A (en) | The CAR-T cell preparation method and application of CD133 is targeted based on base editor | |
CN109022363A (en) | A kind of CD-133-CAR-T system constituting method based on PiggyBac carrier | |
CN117377683A (en) | New antigenic peptide and application thereof in treating BRAF gene mutation related diseases | |
CN110564766A (en) | Preparation method of whole genome expression vector pBR322-DHN3 | |
CN113073086A (en) | African swine fever virus gene deletion strain and construction method and application thereof | |
KR20180054373A (en) | A transformant comprising MYH3 gene and use thereof | |
RU2726541C1 (en) | Recombinant human breast cancer cell line brcch4e-134, expressing human prostate-specific membrane antigen | |
CN111961651A (en) | Gene recombinant PD-1 antibody autocrine human gamma T cell and construction method and application thereof | |
KR20210137427A (en) | CAR T cell methods and constructs | |
CN111100874A (en) | Targeting vector, method for constructing BAC clone by integrating exogenous gene to mouse DC-SIGN exon 7 site and application | |
CN114891114A (en) | Intracellular signal domain for construction of chimeric antigen receptor | |
CN110819589B (en) | Method for enhancing immune effector cell function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |